BioSpace News Archive

PYA, a leading certified public accounting and professional services firm, awarded 490 BioTech the inaugural Tom Ballard Innovation Award Friday, March 12, 2021

CannTrust Holdings Inc. (“CannTrust” or the “Company”) announced today that Mark Litwin has resigned from the Company’s board of directors (the “Board”) and the boards of directors of all subsidiaries

Health Logic Interactive Inc. (“Health Logic” or the “Company”) (NEX: CHIP), is pleased to announce the hiring of Mr. David Barthel, as the Chief Executive Officer for Health Logic.

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial designed to further confirm the clinical utility of MammaPrint® risk scoring when determining a breast cancer patient’s need for chemotherapy, was published in The Lancet Oncology, and can be viewed online here.

AIDS Healthcare Foundation (AHF), the world’s largest provider of HIV/AIDS care globally, fully supports a recent call in an editorial by The Lancet journal for the appointment of a high-level leader or a group with a moral and authoritative voice to act as a liaison between countries in ensuring equitable and fair access to COVID-19 vaccines around the world.

Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that leading independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended Neos Therapeutics stockholders vote “FOR” the pending merger with Aytu BioScience,

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

Eurofins adds virus variant monitoring capabilities to its commercially available SARS-CoV-2 test portfolio.

Paragonix Technologies, Inc. announced today that Lisa Anderson, Ph.D., has been elevated to the role of CEO.